Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
Appointed director
Statera Biopharma, Inc. (CBLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/01/2023 8-K Quarterly results
01/20/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
11/15/2022 8-K Quarterly results
11/04/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: " ",
" "
10/27/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
10/17/2022 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: " "
09/27/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/03/2022 8-K Changes in Registrant's Certifying Accountant, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: " "
06/22/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
04/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod FORT COLLINS, CO., April 13, 2022 /Globe Newswire/ — Statera Biopharma , a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company has agreed to enter into a strategic agreement with Coeptis Therapeutics, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, to sell Statera’s rights to Entolimod and other related toll-like receptor 5 agonists. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Coeptis financing. “Coeptis’ commitment to cancer the..."
04/15/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
04/13/2022 8-K/A Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/31/2022 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
Docs: "Resignation Letter of Randy Saluck"
03/25/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/22/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: " "
03/08/2022 8-K/A Quarterly results
02/25/2022 8-K Quarterly results
02/22/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: " "
02/07/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: " ",
" ",
" ",
" ",
" "
01/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of McGuireWoods LLP"
12/20/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID"
12/14/2021 8-K Quarterly results
12/01/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
11/12/2021 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
11/10/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
09/29/2021 8-K Quarterly results
09/28/2021 8-K Quarterly results
09/01/2021 8-K Quarterly results
08/17/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy